Last reviewed · How we verify
Beconase Aq (beclometasone dipropionate)
Beconase Aq (beclometasone dipropionate) is a corticosteroid medication originally developed by GlaxoSmithKline. It is a small molecule that targets the probable G-protein coupled receptor 97 and is used to treat various respiratory conditions, including allergic rhinitis, asthma, and nasal polyps. Beconase Aq was first approved by the FDA in 1976 and is still commercially available. Key safety considerations include potential local side effects such as nasal irritation and systemic effects like adrenal suppression. The medication's commercial status is not explicitly stated, but it is likely to be off-patent.
At a glance
| Generic name | beclometasone dipropionate |
|---|---|
| Drug class | Corticosteroid |
| Target | Probable G-protein coupled receptor 97 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Allergic rhinitis
- Asthma
- Asthma management
- Nasal polyp
- Rhinitis
- Vasomotor rhinitis
Common side effects
- Nasopharyngeal irritation
- Sneezing attacks
- Headache
- Nausea
- Lightheadedness
- Nasal stuffiness
- Nosebleeds
- Rhinorrhea
- Tearing eyes
- Dryness and irritation of nose and throat
- Unpleasant taste
- Unpleasant smell
Serious adverse events
- Nasal septum perforation
- Ulceration of nasal mucosa
- Wheezing
- Cataracts
- Glaucoma
- Increased intraocular pressure
- Anaphylactoid/anaphylactic reactions
- Angioedema
- Bronchospasm
- Growth suppression
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beconase Aq CI brief — competitive landscape report
- Beconase Aq updates RSS · CI watch RSS
- portfolio CI